Effect of chemotherapy on health-related quality of life among early-stage ovarian cancer survivors: a study from the population-based PROFILES registry

  • C.S. Bhugwandass Slingeland Hospital; Gynecological Oncology Centre South
  • J.M.A. Pijnenborg Gynecological Oncology Centre South; Elisabeth-TweeSteden Hospital http://orcid.org/0000-0002-6138-1236
  • B. Pijlman Gynecological Oncology Centre South; Jeroen Bosch Hospital
  • N.P.M. Ezendam Gynecological Oncology Centre South; Tilburg University; Comprehensive Cancer Centre
Keywords: Ovarian cancer, early-stage disease, chemotherapy, neuropathy, health-related quality of life, peripheral neuropathy

Abstract

Background

There is wide variation in the application of adjuvant chemotherapy in early-stage epithelial ovarian cancer. Our aim was to assess differences in health-related quality of life (hrqol) between patients with early-stage ovarian cancer who did or did not receive chemotherapy as adjuvant treatment.

Methods

All patients diagnosed with early-stage ovarian cancer between 2000 and 2010 within the population-based Eindhoven Cancer Registry (n = 191) were enrolled in this study. Patients were requested to complete questionnaires, including the cancer-specific (qlq-C30) and ovarian cancer-specific (qlq-OV28) quality of life measures from the European Organisation for Research and Treatment of Cancer. Primary outcome measures were the generic- and cancer-specific domain scores for hrqol in ovarian cancer survivors.

Results

Of the 107 patients (56%) who returned the questionnaires, 57 (53.3%) had received adjuvant chemotherapy and 50 (46.7%) had been treated with surgery alone. Significant differences in hrqol between those groups were found in the symptom scales for peripheral neuropathy, attitude toward sickness, and financial situation, with worse scores in the chemotherapy group.

Conclusions

Results of our study show that patients who receive adjuvant chemotherapy have a significantly worse score for 3 aspects of hrqol. Efforts should be made to reduce use of adjuvant chemotherapy in early-stage ovarian cancer. Moreover, preventive strategies to improve long-term quality of life for those who need adjuvant chemotherapy should be explored.

Author Biographies

C.S. Bhugwandass, Slingeland Hospital; Gynecological Oncology Centre South
Department of Surgery
J.M.A. Pijnenborg, Gynecological Oncology Centre South; Elisabeth-TweeSteden Hospital
Elisabeth-TweeSteden Hospital
B. Pijlman, Gynecological Oncology Centre South; Jeroen Bosch Hospital
Department of Obstetrics and Gynaecology
N.P.M. Ezendam, Gynecological Oncology Centre South; Tilburg University; Comprehensive Cancer Centre

Centre of Research on Psychology in Somatic Diseases, Department of Medical and Clinical Psychology

Published
2016-12-22
How to Cite
Bhugwandass, C., Pijnenborg, J., Pijlman, B., & Ezendam, N. (2016). Effect of chemotherapy on health-related quality of life among early-stage ovarian cancer survivors: a study from the population-based PROFILES registry. Current Oncology, 23(6), e556-e562. https://doi.org/10.3747/co.23.3243
Section
Cancer Rehabilitation and Survivorship